These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 28572733)
1. The Jordan Food and Drug Administration: Comparison of its Registration Process with Australia, Canada, Saudi Arabia and Singapore. Haqaish WSA; Obeidat H; Patel P; Walker S Pharmaceut Med; 2017; 31(1):21-30. PubMed ID: 28572733 [TBL] [Abstract][Full Text] [Related]
2. The Saudi Arabia Food and Drug Authority: An Evaluation of the Registration Process and Good Review Practices in Saudi Arabia in Comparison with Australia, Canada and Singapore. Hashan H; Aljuffali I; Patel P; Walker S Pharmaceut Med; 2016; 30():37-47. PubMed ID: 26834481 [TBL] [Abstract][Full Text] [Related]
3. The Turkish Medicines and Medical Devices Agency: Comparison of Its Registration Process with Australia, Canada, Saudi Arabia, and Singapore. Mashaki Ceyhan E; Gürsöz H; Alkan A; Coşkun H; Koyuncu O; Walker S Front Pharmacol; 2018; 9():9. PubMed ID: 29422861 [No Abstract] [Full Text] [Related]
4. The South African Medicines Control Council: Comparison of Its Registration Process With Australia, Canada, Singapore, and Switzerland. Keyter A; Salek S; Banoo S; Walker S Front Pharmacol; 2019; 10():228. PubMed ID: 30923501 [No Abstract] [Full Text] [Related]
5. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners. Hotaki LT; Shrestha A; Bennett MP; Valdes IL; Lee SH; Wang Y; Spillman D; MacAulay T; Hunt M; Gervais J; Mafi M; Panetta V; Looi YH; Shum M; Atiek E; Meincke R; Rohr UP; Ainbinder D; Boehm-Cagan A; Luxenburg O; Cerqueira MR; Mouawad LS; Thees MFRES; Prasad K; de Claro RA Ther Innov Regul Sci; 2023 Jul; 57(4):875-885. PubMed ID: 37072651 [TBL] [Abstract][Full Text] [Related]
6. The Regulatory Review Process in South Africa: Challenges and Opportunities for a New Improved System. Keyter A; Gouws J; Salek S; Walker S Ther Innov Regul Sci; 2018 Jul; 52(4):449-458. PubMed ID: 29848046 [TBL] [Abstract][Full Text] [Related]
7. Concept of biosimilar products in Jordan. Haddadin RD Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Regulatory Review Process in Zimbabwe: Challenges and Opportunities. Sithole T; Mahlangu G; Salek S; Walker S Ther Innov Regul Sci; 2021 May; 55(3):474-489. PubMed ID: 33387356 [TBL] [Abstract][Full Text] [Related]
9. Similarities and Differences of International Practices and Procedures for the Regulation for Active Substance Master Files/Drug Master Files of Human Use: Moving Toward Regulatory Convergence. Matsuhama M; Takishita T; Kuribayashi R; Takagi K; Wakao R; Mikami K J Pharm Pharm Sci; 2016; 19(2):290-301. PubMed ID: 27518176 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the registration process of the medicines control authority of Zimbabwe with Australia, Canada, Singapore, and Switzerland: benchmarking best practices. Sithole T; Salek S; Mahlangu G; Walker S Expert Rev Clin Pharmacol; 2022 Jan; 15(1):109-119. PubMed ID: 34645359 [TBL] [Abstract][Full Text] [Related]
11. Biosimilars according to Jordan Food and Drug Administration regulations. Abdelaziz AA Ann Pharm Fr; 2022 May; 80(3):248-252. PubMed ID: 34756928 [TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical Pricing Policies and Procedures in Saudi Arabia: A Narrative Review. Khan TM; Emeka P; Suleiman AK; Alnutafy FS; Aljadhey H Ther Innov Regul Sci; 2016 Mar; 50(2):236-240. PubMed ID: 30227009 [TBL] [Abstract][Full Text] [Related]
13. Registration of similar biological products--Singapore's approach. Poh J; Tam KT Biologicals; 2011 Sep; 39(5):343-5. PubMed ID: 21783381 [TBL] [Abstract][Full Text] [Related]
14. Risk management frameworks for human health and environmental risks. Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Food and Drugs Authority, Ghana Regulatory Review Process: Challenges and Opportunities. Owusu-Asante M; Darko DM; Asamoah-Okyere KD; Asante-Boateng S; Kermad A; Walker S; Salek S Ther Innov Regul Sci; 2023 Mar; 57(2):372-385. PubMed ID: 36352343 [TBL] [Abstract][Full Text] [Related]
16. [Procedures and methods of benefit assessments for medicines in Germany]. Bekkering GE; Kleijnen J Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813 [TBL] [Abstract][Full Text] [Related]
17. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
18. Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices. Rahalkar H; Sheppard A; Salek S Front Pharmacol; 2021; 12():711361. PubMed ID: 34434109 [No Abstract] [Full Text] [Related]
19. Evaluation of the Performance of the Gulf Cooperation Council Centralised Regulatory Review Process: Strategies to Improve Product Authorisation Efficiency and Quality. Hashan HM; Al-Muteb SK; Alismail IA; Alsaleh ON; Alkherb ZM; McAuslane N; Walker SR Pharmaceut Med; 2022 Aug; 36(4):223-231. PubMed ID: 35767216 [TBL] [Abstract][Full Text] [Related]
20. Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice. Rodier C; Bujar M; McAuslane N; Patel P; Liberti L Ther Innov Regul Sci; 2021 Jan; 55(1):118-128. PubMed ID: 32617911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]